Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co.

Upstream Bio (NASDAQ:UPB) had its price objective upped by JPMorgan Chase & Co. from $8.00 to $9.00 in a research report released on Friday,Benzinga reports. They currently have a neutral rating on the stock.

Several other brokerages also recently issued reports on UPB. HC Wainwright assumed coverage on shares of Upstream Bio in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 price objective on the stock. Truist Financial cut their target price on shares of Upstream Bio to $25.00 and set a “buy” rating for the company in a research note on Tuesday. Mizuho reduced their price target on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Upstream Bio in a research report on Monday, August 3rd. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $29.67.

Upstream Bio Stock Performance

NASDAQ UPB opened at $7.07 on Friday. Upstream Bio has a twelve month low of $5.85 and a twelve month high of $33.68. The stock has a market capitalization of $387.22 million, a PE ratio of -2.44 and a beta of 1.26. The stock has a 50-day simple moving average of $6.81 and a 200 day simple moving average of $9.90.

Upstream Bio (NASDAQ:UPB) last released its earnings results on Tuesday, August 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.01. Upstream Bio had a negative return on equity of 48.40% and a negative net margin of 4,955.67%.The firm had revenue of $0.77 million for the quarter, compared to analyst estimates of $0.56 million. As a group, equities research analysts forecast that Upstream Bio will post -2.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Upstream Bio

A number of institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC acquired a new stake in Upstream Bio in the 1st quarter valued at $115,000. Woodline Partners LP lifted its holdings in shares of Upstream Bio by 5.8% during the first quarter. Woodline Partners LP now owns 557,063 shares of the company’s stock valued at $3,409,000 after acquiring an additional 30,552 shares during the period. Creative Planning acquired a new stake in shares of Upstream Bio in the 2nd quarter valued at $154,000. JPMorgan Chase & Co. boosted its stake in shares of Upstream Bio by 8.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock valued at $181,000 after purchasing an additional 1,275 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Upstream Bio by 83.0% in the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after purchasing an additional 1,440 shares during the last quarter.

Key Headlines Impacting Upstream Bio

Here are the key news stories impacting Upstream Bio this week:

• Positive Sentiment: JPMorgan raised its price target for Upstream Bio (UPB) from $8 to $9 while maintaining a “Neutral” rating. The revised target implies approximately 27.3% upside from the referenced share price, providing a modest positive catalyst despite the unchanged cautious rating. Benzinga article
• Positive Sentiment: HC Wainwright retained its “Buy” rating and $36 price target, indicating substantial potential upside if Upstream Bio’s pipeline and development plans progress successfully. MarketBeat analyst coverage
• Neutral Sentiment: HC Wainwright’s revised forecasts continue to project losses, including estimated 2026 earnings of negative $3.09 per share and negative $0.79 and $0.82 per share for the third and fourth quarters, respectively. The firm’s “Buy” rating remains unchanged, but the estimates point to a lengthy path toward profitability.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across 2026–2030: 2027 to negative $3.31 from negative $3.09, 2028 to negative $3.13 from negative $2.92, 2029 to negative $3.56 from negative $3.35, and 2030 to negative $3.84 from negative $3.42. These broader expected losses may weigh on investor sentiment and offset the benefit of JPMorgan’s target increase. MarketBeat analyst estimates

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.